This activity is supported by educational grants from AbbVie, Ariad Pharmaceuticals, Inc., Baxalta US Inc., Bristol-Myers Squibb, Celgene, Genentech, Inc., Gilead, Incyte Corporation, Infinity Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Pharmacyclics LLC and Janssen Biotech, Inc., Seattle Genetics, Takeda Oncology, and TG Therapeutics, Inc.
Click here to download brochure
Now in its 20th year, the annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma is designed to facilitate clinician application of the wealth of emerging data in treating hematologic malignancies, choosing appropriate treatment based upon patient and tumor characteristics, and applying novel management strategies to their practices to improve the care of patients.
New for this year! We have extended the Congress to a 3-day meeting. This speaks volumes to the tremendous amount of progress and wealth of new data in a variety of hematologic malignancies. This year’s program will focus on key clinical topics in the field, with a particular focus on leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, benign hematologic disorders, and mitigation and management of adverse events. Patient cases will be presented and discussed with the audience in a manner designed to engage their participation and in the context of methods to practically apply pivotal trial data to everyday practice. Additionally, the well-known and highly interactive Medical Crossfire® discussion panels will allow for exploration of some of the most challenging topics for which there may be many potential approaches to care.
This highly practical and interactive forum will provide a unique opportunity for oncologists and other healthcare professionals to learn from and interact with leading expert national faculty in order to increase their clinical knowledge, apply new data to practice, and ultimately improve patient outcomes.
At the conclusion of this symposium, you should be better prepared to:
Community Practice Connections™: New Frontiers in Immuno-Oncology for Microsatellite Instability-High Cancers
Aug 29, 2018
Aug 31, 2018